Blonder Tongue Laboratories, Inc.

As of June 30, 2024, Blonder Tongue Laboratories, Inc. has 14.47M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 0.12, and the price-to-book ratio stands at -0.04.

As of June 30, 2024, Blonder Tongue Laboratories, Inc. trades at an EV/EBITDA multiple of 44.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Blonder Tongue Laboratories, Inc. trades at an EV/FCF ratio of 3.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, Blonder Tongue Laboratories, Inc. maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,030.45, indicating conservative leverage, while an interest coverage ratio of 0.26 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -10.58, reflecting losses generated across the asset base. Inventory turnover of 2.62 indicates how many times Blonder Tongue Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on January 5, 2026, Blonder Tongue Laboratories, Inc.'s stock has declined approximately 61.37% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.

Over the twelve months ended June 30, 2024, Blonder Tongue Laboratories, Inc. posted a gross margin of 31.21, reflecting its pricing power and cost economics. The operating margin of -5.66 and net profit margin of -10.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 122.20, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 75.25, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Blonder Tongue Laboratories, Inc. shareholders.

As of June 30, 2024, Blonder Tongue Laboratories, Inc. has an Altman Z-Score of -4.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.